In leukemia, mebendazole modulates MYB degradation by interfering with the heat shock protein 70 and exhibit the ability of impairing acute myeloid leukemia (AML) growth in vivo involving SP70/HSC70 chaperone pathway. This evidence concerns the gene HSPA8 and acute myeloid leukemia.